JP2011505341A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505341A5
JP2011505341A5 JP2010535064A JP2010535064A JP2011505341A5 JP 2011505341 A5 JP2011505341 A5 JP 2011505341A5 JP 2010535064 A JP2010535064 A JP 2010535064A JP 2010535064 A JP2010535064 A JP 2010535064A JP 2011505341 A5 JP2011505341 A5 JP 2011505341A5
Authority
JP
Japan
Prior art keywords
group
nhc
alkyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010535064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/084193 external-priority patent/WO2009067600A2/en
Publication of JP2011505341A publication Critical patent/JP2011505341A/ja
Publication of JP2011505341A5 publication Critical patent/JP2011505341A5/ja
Pending legal-status Critical Current

Links

JP2010535064A 2007-11-21 2008-11-20 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤 Pending JP2011505341A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98955107P 2007-11-21 2007-11-21
PCT/US2008/084193 WO2009067600A2 (en) 2007-11-21 2008-11-20 Biaryl pde4 inhibitors for treating inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014046962A Division JP2014185149A (ja) 2007-11-21 2014-03-10 炎症を治療するためのビアリールｐｄｅ４阻害薬

Publications (2)

Publication Number Publication Date
JP2011505341A JP2011505341A (ja) 2011-02-24
JP2011505341A5 true JP2011505341A5 (enExample) 2013-03-14

Family

ID=41650335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535064A Pending JP2011505341A (ja) 2007-11-21 2008-11-20 炎症性、心血管およびｃｎｓ障害を治療するビアリールｐｄｅ４抑制剤

Country Status (6)

Country Link
EP (1) EP2222638A2 (enExample)
JP (1) JP2011505341A (enExample)
CN (1) CN102089279A (enExample)
AU (1) AU2008326381B2 (enExample)
CA (1) CA2722582A1 (enExample)
WO (1) WO2009067600A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
EP2674417A3 (en) 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
WO2010059838A2 (en) * 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2600864B1 (en) * 2010-08-04 2019-01-09 University Of Virginia Patent Foundation Compositions and methods for treating inflammatory diseases
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
US9540361B2 (en) * 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
CN103012255B (zh) * 2011-09-21 2014-06-11 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
CN102603676B (zh) * 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
CN103012408B (zh) * 2012-11-28 2015-02-04 中国科学院广州生物医药与健康研究院 依匹斯汀的合成方法
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
CN106458896A (zh) 2014-03-14 2017-02-22 沃克哈特有限公司 (2s,5r)‑6‑(苄氧基)‑7‑氧代‑1,6‑二氮杂二环[3.2.1]辛烷‑2‑羧酸钠的制备方法
LT3209655T (lt) 2014-10-24 2021-01-11 Landos Biopharma, Inc. Medicininiai preparatai į lantionino sintezę c panašaus baltymo 2 pagrindu
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3483142B1 (en) 2016-07-05 2025-10-15 Beijing Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
WO2019108418A1 (en) 2017-11-30 2019-06-06 Landos Biopharma, Inc. Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith
EP3733659B1 (en) 2017-12-29 2023-12-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
CN110041253B (zh) * 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
WO2020219615A1 (en) * 2019-04-23 2020-10-29 Tetra Discovery Partners, Inc. 3-hydroxy-2-phenyl-6-(pyrazol-4-ylmethyl)pyridine derivatives as pde4d inhibitors
CN113748109B (zh) 2019-12-20 2023-07-21 朗多生物制药股份有限公司 羊毛硫氨酸c样蛋白2配体、用所述配体制备的细胞以及使用所述配体的疗法
CN113912593A (zh) * 2020-07-10 2022-01-11 启元生物(杭州)有限公司 一种氘代吡啶酮类化合物及其应用
EP4215526A4 (en) 2020-09-18 2024-10-16 Shanghai Pharmaceuticals Holding Co., Ltd. HETEROCYCLIC CARBONYL COMPOUND AND ITS USE
CN112374984A (zh) * 2020-11-06 2021-02-19 苏州求索生物科技有限公司 一种2-溴-4-羟基苯甲醚的制备工艺
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
CN117756794B (zh) * 2023-12-18 2024-07-16 和径医药科技（上海）有限公司 一种含氮杂环类化合物及其制备方法和应用
WO2025240840A1 (en) * 2024-05-17 2025-11-20 Shionogi & Co., Ltd. Aromatic heterocycle derivatives and aromatic carbocycle derivatives having pde4d inhibitory activity
CN118994115B (zh) * 2024-07-29 2025-09-09 宁波大学 治疗甲基苯丙胺成瘾及认知障碍的新化合物制备和应用
CN119819277B (zh) * 2025-03-17 2025-05-27 昆明医科大学 一种基于BINAM的β-环糊精衍生物手性固定相及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3778430D1 (en) * 1986-06-20 1992-05-27 Idemitsu Kosan Co Polycarbonate.
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
EP0793662A1 (en) * 1994-11-23 1997-09-10 Neurogen Corporation Aminomethyl aryl compounds; dopamine receptor subtype selective ligands
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
FR2754260B1 (fr) * 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999031062A1 (en) * 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Novel pyridine compounds
JP2002507598A (ja) * 1998-03-26 2002-03-12 スージェン・インコーポレーテッド チロシン蛋白質キナーゼを調節するためのヘテロ環式化合物のファミリー
JP4979157B2 (ja) * 1998-09-09 2012-07-18 バイオリポックス アーべー 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
WO2001030764A1 (en) * 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
WO2002072009A2 (en) * 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
EP1559422B1 (en) * 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20060293339A1 (en) * 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
CA2520804A1 (en) * 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
US7557143B2 (en) * 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
EP1689383B1 (en) * 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2551610A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
CA2589322A1 (en) * 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
WO2006066978A1 (en) * 2004-12-23 2006-06-29 Galderma Research & Development Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics
MX2007008290A (es) * 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
EP2774925B1 (en) * 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
AU2006336504C9 (en) * 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
WO2007079186A2 (en) * 2005-12-30 2007-07-12 Merck & Co., Inc. 1, 3-oxazolidin-2-one derivatives useful as cetp inhibitors
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
EP2036887A1 (en) * 2006-06-28 2009-03-18 Sanwa Kagaku Kenkyusho Co., Ltd Novel 6-5 bicycic heterocyclic derivative and medical use thereof
CN101522614B (zh) * 2006-08-09 2014-06-25 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的化合物
EP2132197A2 (en) * 2007-03-21 2009-12-16 Almirall, S.A. Substituted pyrimidines as adenosine receptor antagonists
EP2674417A3 (en) * 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
FR2932180B1 (fr) * 2008-06-04 2012-08-10 Centre Nat Rech Scient Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline

Similar Documents

Publication Publication Date Title
JP2011504505A5 (enExample)
AU663149B2 (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
RU2573834C2 (ru) ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
AU2008326309C1 (en) Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
CN109790135B (zh) 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
Abdelazeem et al. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile
JP2018519323A5 (enExample)
BG106678A (bg) ПИРАЗОЛО [4,3 - d] ПИРИМИДИНОВИ ПРОИЗВОДНИ
JP2007510689A (ja) 新規ピリダジン−３（２ｈ）−オン誘導体
EP2222638A2 (en) Biaryl pde4 inhibitors for treating inflammation
KR20180032645A (ko) Ror 감마 조절제로서의 신규한 화합물
JP2011504183A5 (enExample)
JP2012188363A (ja) アザベンゾイミダゾロン誘導体
JP2002088073A (ja) 抗アンドロゲン剤
JP2005533805A (ja) 新規化合物
TW201609707A (zh) 新穎之經取代嘧啶化合物
CA2793709A1 (en) Therapeutic agent or prophylactic agent for fibromyalgia
WO2012028106A1 (en) Deuterium-enriched heterocyclic compounds as kinase inhibitors
JP2006528624A (ja) Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体
JP2008520644A (ja) オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
KR20150046456A (ko) 신규한 항진균성 옥소다이하이드로피리딘카보하이드라자이드 유도체
HK40070781A (en) Process for making deuterated hydroxy-benzbromarone and intermediates thereof
WO2025147670A1 (en) Lysine acetyltransferase inhibitors
HK40070781B (en) Process for making deuterated hydroxy-benzbromarone and intermediates thereof
KR101646180B1 (ko) N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제